Research funder · Australia
Phenomics Australia
- Grants since 2016
- 70
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 0
- Funded works, all time
- 0
Grants
2026
Developing novel models of cardiomyopathy for therapeutic testing
2026
FDA-approved therapeutic compound library screen to discover new drugs to treat ARID1A mutant ovarian cancer
2026
Generation of mouse models of inherited heart failure to test the efficacy of novel stem cell based therapies
2026
Developing new tools to enable the translation of complement therapeutics for human disease
2026
Novel Immunologic Intervention for Interferon Driven Autoimmune Diseases
2026
High throughput screening to identify new therapeutic strategies for mucinous ovarian cancer patients
2026
High-throughput identification of targets that improve kidney organoid generation protocols
2026
Development of Humanised Mice to Improve the Translatability for Cardiopulmonary Disease
2026
A high throughput human organoid model to measure effects of co-cultured immune cells
2026
Testing precision medicines for Alzheimer's disease using advanced 3D human brain models
2026
Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal
2026
Developing transcriptomic and morphological profiling of macrophages to mine the microbiome
2026
Identifying patient-specific treatments that target plasticity in colorectal cancer via high throughput screening
2026
Development of iPSC models for ASO screening for TRAPPC4 neurodevelopmental disorder
2026
New therapeutic strategies and targets to suppress acute kidney injury
2026
Scalable Allogeneic Tregs Platform for autoimmune diseases
2026
Developing a human induced pluripotent stem cell reporter line for heart valve disease modelling
2026
Generation of Oral Carcinoma Patient-Derived Organoids for Personalised Cancer Research
2026
CRISPR phenotype screen and machine learning to understand Motor Neuron Disease pathogenesis
2026
Developing humanised models of Diamond Blackfan Anaemia Syndrome
2026
Targeting Cholesin to Control Viral Immunity
2026
Gene therapy to cure primary immunodeficiencies
2026
Identifying re-purposed drugs for KCNT1 epilepsy using cell and animal models
2026
Generation of Humanised CYP21A2 Mouse Models to Enable Translational Genome Editing Therapies for Congenital Adrenal Hyperplasia
2026
Identification of personalised treatment strategies for breast cancer through high-throughput screening
2026
Development of a Primary CNS Lymphoma (PCNSL)-Brain Organoid co-culture model
2026
Tick tock, tick tock… Mechanisms pacing the Hox clock
2026
Screening for new treatments for glomerular disease with a new stem cell reporter line
2026
Engineering genetic mouse models of severe childhood epilepsy to test the efficacy of venom peptides as a therapeutic strategy
2026
Developing a Scalable Hydrogel Discovery Platform for 3D Cancer Modelling
2026
Studying enhancer function and the genetics of blood cell development from human induced pluripotent stem cells
2026
A novel therapeutic intervention for genetic epilepsies using spider-venom peptides
2026
Identifying which processes activated by p53 are critical to prevent tumour development to supportthe design of novel cancer therapies
2026
Developing reporter lines to enhance human kidney micro-organoids
2026
MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation to: MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation
2026
The role of ferroptosis and oxidative stress in regulating immunity
2026
Target identification of novel anti-cancer therapeutic
2026
Methodology development for high-throughput compound screeing of primary human immune cell cytotoxicity in 3D
2026
In vivo functional characterisation of candidate pathogenic variants in ubiquitin proteasome components
2026